The ACTR1B Knockout Ca Ski Polyclonal Cells represent a CRISPR/Cas9-mediated polyclonal knockout cell population derived from the Ca Ski human cervical carcinoma cell line, engineered to disrupt the ACTR1B gene encoding the actin-related protein 1B component of the dynactin complex. This polyclonal knockout pool provides a heterogeneous loss-of-function model for studying dynactin-dependent processes without clonal selection artifacts. The CRISPR/Cas9-edited cells offer a versatile tool for investigating ACTR1B function in cancer cell biology, cytoskeletal dynamics, and intracellular trafficking.
The parental Ca Ski cell line is a well-established model of human cervical squamous cell carcinoma, originally isolated from a mesenteric metastasis and characterized by the stable integration of both HPV-16 and HPV-18 genomes. These cells express the viral oncoproteins E6 and E7, which drive oncogenesis by inactivating p53 and Rb, respectively, and provide a clinically relevant HPV-positive system for studying cervical cancer pathogenesis. The Ca Ski line is widely utilized for examining HPV-host interactions, viral oncogene regulation, and mechanisms of tumor cell migration and invasion.
ACTR1B encodes a subunit of the dynactin multiprotein complex that functions as an essential cofactor for the microtubule minus-end-directed motor dynein. Dynactin, through its interaction with dynein and various cargo adaptors, mediates retrograde transport of vesicles, organelles, and protein complexes along microtubules. ACTR1B heterodimerizes with ACTR1A to form an actin-like filament at the dynactin base, facilitating cargo recognition and dynein processivity. Upstream regulators of ACTR1B expression include the transcription factors E2F1 and MYC, while its activity is modulated by cell cycle kinases such as CDK1 and Aurora A kinase. ACTR1B-dynactin interacts with DCTN1?CDCTN6, the dynein intermediate chain, and CAPZA, and functions downstream of these complexes to orchestrate pericentrosomal Golgi positioning, mitotic spindle assembly, and endosomal maturation. Disruption of ACTR1B impairs dynein-mediated retrograde transport, leading to defective organelle distribution, chromosome segregation errors, and altered autophagosome-lysosome fusion.
In the context of Ca Ski cells, ACTR1B knockout is expected to perturb the intracellular trafficking pathways critical for HPV oncoprotein function and cellular transformation. HPV E6 and E7 rely on host transport machinery for proper localization and degradation of tumor suppressors; dynactin-dependent retrograde transport may influence E6/E7 protein stability and signaling. Moreover, ACTR1B loss may compromise mitotic fidelity and promote chromosomal instability, a hallmark of HPV-driven cancers. The model also enables investigation of autophagic defects potentially linked to cervical cancer progression. By disrupting ACTR1B in Ca Ski cells, researchers can evaluate how dynactin dysfunction impacts HPV-mediated oncogenesis, drug sensitivity, and metastatic behavior, providing insights into cytoskeletal contributions to cervical malignancy.
This polyclonal knockout product is suited for a range of functional studies, including high-resolution imaging of organelle dynamics, live-cell tracking of vesicle movement, and co-immunoprecipitation to assess dynactin complex integrity. Representative assays such as immunofluorescence for Golgi morphology and microtubule organization, cell migration and invasion assays, and RNA-seq-based transcriptomic profiling allow systematic dissection of ACTR1B-dependent pathways. The Ca Ski background further supports analyses of HPV E6/E7 expression and function under dynactin disruption. Researchers may employ this model to explore dynactin??s role in neurodegenerative disease-relevant processes, as ACTR1B mutations are associated with Perry syndrome. For additional technical information or to discuss custom applications, please contact Ascent Research.
